RxDoctor Payments Data

John Heidrick, DO

Family Medicine · Bakersfield, CANPI 1447252754

Payments from drug & device makers

$17,487in general payments, 2019–2025

Across 1,022 payments — averaging $17.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$3K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • AbbVie$1K
  • Lilly USA, LLC$1K
  • Amarin Pharma, Inc.$1K
  • Boehringer Ingelheim$773
  • plus $8K from 54 others

What the payments were for

  • Consulting fees$1201%
  • Speaking & faculty fees$4102%
  • Food & beverage$16,69395%
  • Education$1241%
  • Gifts$1401%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen168$3,491
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC136$1,498
AbbVie(2 entities)123$1,478
Lilly USA, LLC89$1,302
Amarin Pharma, Inc.80$1,113
Boehringer Ingelheim39$773
AstraZeneca26$748
Merck35$604
Supernus Pharmaceuticals, Inc.21$401
Sanofi-aventis U.S. LLC7$393
Pfizer19$393
Novartis26$373
Esperion Therapeutics, Inc.16$300
Otsuka America Pharmaceutical, Inc.16$290
Sunovion Pharmaceuticals Inc.25$281
Ironwood Pharmaceuticals, Inc16$281
Novo Nordisk14$258
Takeda Pharmaceuticals U.S.A., Inc.20$252
GSK7$226
Astellas Pharma US Inc11$225
Smith+Nephew15$195
Biohaven Pharmaceuticals, Inc.12$174
Teva Pharmaceuticals USA, Inc.4$172
Radius Health, Inc.8$167
Sekisui Diagnostics LLC1$140
Bayer6$140
Lucid Diagnostics Inc.7$130
Axsome Therapeutics, Inc.1$124
Biosense Webster, Inc.1$122
Biohaven Pharmaceutical Holding Company Ltd.9$117
Arbor Pharmaceuticals, Inc.8$117
Sanofi1$110
Sanofi Pasteur Inc.4$81
Kowa Pharmaceuticals America, Inc.3$79
Exact Sciences3$75
Idorsia Pharmaceuticals US Inc3$70
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)3$66
Bioventus LLC3$62
Alk-abello, Inc3$54
Mylan Specialty L.p.3$53
Lundbeck LLC3$51
Phathom Pharmaceuticals, Inc.4$49
Nestle Healthcare Nutrition Inc.2$49
Johnson & Johnson(2 entities)2$42
Almatica Pharma LLC2$42
Electromed, Inc.2$36
Shield Therapeutics Inc1$33
Baxter Healthcare1$32
Vertex1$29
Eisai Inc.2$23
Ardelyx, Inc.1$21
Ultragenyx Pharmaceutical Inc.1$20
Corcept Therapeutics1$19
Amryt Pharma Holdings Ltd1$18
Abbott1$18
Bausch & Lomb Americas Inc.1$18
Alfasigma USA, Inc.1$16
Philips North America LLC1$16
Therapeuticsmd, Inc.1$15
Aimmune Therapeutics, Inc.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,487 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$128,325
Medicare patients
247
Services billed
17,716

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide43$60,225
OzempicSemaglutide45$48,561
Synjardy XrEmpagliflozin/Metformin Hcl42$39,952
Repatha SureclickEvolocumab27$26,032
XareltoRivaroxaban18$24,984
VascepaIcosapent Ethyl37$21,867
FarxigaDapagliflozin Propanediol11$17,751
Tresiba Flextouch U-200Insulin Degludec23$17,708
LinzessLinaclotide12$10,678
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog11$9,610
Praluent PenAlirocumab13$8,531
Icosapent Ethyl22$7,952
NexlizetBempedoic Acid/Ezetimibe16$7,288
EdarbyclorAzilsartan Med/Chlorthalidone12$4,767
Levothyroxine Sodium180$3,143

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$1,302$60,22543 claims
Novo NordiskOzempic$258$48,56145 claims
Boehringer IngelheimSynjardy Xr$773$39,95242 claims
Johnson & JohnsonXarelto$42$24,98418 claims
AstraZenecaFarxiga$748$17,75111 claims
AbbVieLinzess, Synthroid$1,478$12,15032 claims
Esperion Therapeutics, Inc.Nexlizet$300$7,28816 claims
Arbor Pharmaceuticals, Inc.Edarbyclor$117$4,76712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.

Other family medicine in Bakersfield

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →